HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frank Speleman Selected Research

Neuroblastoma

1/2022The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples.
1/2022Cellular senescence in neuroblastoma.
12/2021From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma.
9/2021MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation.
4/2021A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.
1/2020Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
1/2020The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.
7/2019Author Correction: Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.
6/2019Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors.
1/2019Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frank Speleman Research Topics

Disease

85Neuroblastoma
01/2022 - 01/2003
81Neoplasms (Cancer)
01/2022 - 07/2003
15Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2020 - 11/2010
13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
12/2020 - 04/2010
10Leukemia
11/2017 - 04/2010
7Carcinogenesis
01/2018 - 01/2009
4Medulloblastoma
05/2015 - 07/2012
3Neoplasm Metastasis (Metastasis)
01/2013 - 03/2010
3Chromosome Aberrations (Chromosome Abnormalities)
07/2012 - 01/2002
2Ewing Sarcoma (Sarcoma, Ewing)
01/2022 - 03/2014
2Osteosarcoma (Osteogenic Sarcoma)
01/2022 - 03/2014
2Rhabdomyosarcoma
01/2022 - 03/2014
2Hypoxia (Hypoxemia)
01/2018 - 08/2006
2B-Cell Lymphoma (Lymphoma, B Cell)
12/2014 - 10/2003
2Retinoblastoma (Glioblastoma, Retinal)
03/2014 - 09/2012
2Hodgkin Disease (Hodgkin's Disease)
12/2009 - 07/2007
1Inflammation (Inflammations)
01/2022
1Pleural Effusion (Pleural Effusions)
02/2020
1Brain Stem Neoplasms (Brain Stem Tumor)
02/2020
1Ganglioneuroma
01/2019
1Spontaneous Remission
10/2016
1monosomy Chromosome 7
03/2016
1Pathologic Processes
05/2015

Drug/Important Bio-Agent (IBA)

28MicroRNAs (MicroRNA)IBA
12/2020 - 12/2008
21Proteins (Proteins, Gene)FDA Link
12/2020 - 08/2004
20DNA (Deoxyribonucleic Acid)IBA
01/2022 - 02/2004
19Messenger RNA (mRNA)IBA
11/2018 - 08/2006
13Transcription Factors (Transcription Factor)IBA
09/2021 - 09/2002
9RNA (Ribonucleic Acid)IBA
12/2020 - 07/2009
8Biological ProductsIBA
10/2016 - 08/2007
7Long Noncoding RNAIBA
07/2019 - 12/2014
7Anaplastic Lymphoma KinaseIBA
11/2018 - 10/2003
6Pharmaceutical PreparationsIBA
09/2021 - 01/2013
6Biomarkers (Surrogate Marker)IBA
12/2018 - 11/2010
6ChromatinIBA
05/2018 - 08/2014
5Small Interfering RNA (siRNA)IBA
11/2018 - 07/2012
5Phosphotransferases (Kinase)IBA
11/2018 - 03/2006
5nutlin 3IBA
01/2013 - 10/2006
4Oncogene Proteins (Oncogene Protein)IBA
04/2021 - 07/2012
3Cell-Free Nucleic AcidsIBA
01/2022 - 10/2017
3Adrenergic Agents (Adrenergic Drugs)IBA
09/2021 - 11/2012
3Protein Isoforms (Isoforms)IBA
11/2017 - 05/2008
3Complementary DNA (cDNA)IBA
03/2015 - 09/2003
2Peptides (Polypeptides)IBA
12/2020 - 01/2012
2CrizotinibIBA
11/2018 - 05/2014
2NVP-TAE684IBA
11/2018 - 12/2017
2Indicators and Reagents (Reagents)IBA
01/2018 - 09/2008
2venetoclaxIBA
08/2017 - 12/2014
2Histone ChaperonesIBA
11/2015 - 02/2014
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
09/2014 - 08/2011
2N-Myc Proto-Oncogene ProteinIBA
11/2012 - 04/2004
2Cadherins (E-Cadherin)IBA
01/2012 - 03/2010
2OligonucleotidesIBA
11/2010 - 03/2008
1EnzymesIBA
04/2021
1PolyaminesIBA
04/2021
1Ornithine Decarboxylase (Decarboxylase, Ornithine)IBA
04/2021
1Circular RNAIBA
12/2020
1Proto-Oncogene Proteins c-etsIBA
01/2020
1Histone Deacetylase InhibitorsIBA
01/2019
1Forkhead Box Protein M1IBA
01/2019
1Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2019
1Untranslated RNA (Noncoding RNA)IBA
01/2019
1Circulating MicroRNAIBA
12/2018
1immune RNA (I-RNA)IBA
11/2018
1Tyrosine Kinase InhibitorsIBA
11/2018
1lorlatinibIBA
11/2018
1indolepropanol phosphate (IPP)IBA
11/2018
1Insulin Receptor Substrate ProteinsIBA
11/2018
1ceritinibIBA
11/2018
1Lactate Dehydrogenase 5IBA
11/2018
13' Untranslated Regions (3' UTR)IBA
01/2018
1Nucleosomes (Nucleosome)IBA
01/2018
1RG7388IBA
08/2017
1Tachykinin Receptors (Tachykinin Receptor)IBA
01/2017
1Aprepitant (Emend)FDA Link
01/2017
1Substance PIBA
01/2017
1MethyltransferasesIBA
10/2016
1Membrane Glycoproteins (Membrane Glycoprotein)IBA
10/2016
1Fetal Hemoglobin (Hemoglobin F)IBA
03/2016
1CytokinesIBA
01/2016
1AntioxidantsIBA
01/2016
1Glutathione (Reduced Glutathione)IBA
01/2016
1OTX015IBA
01/2016
1CBLC137IBA
11/2015
1SurvivinIBA
03/2015
1Histones (Histone)IBA
01/2015
1CyclinsIBA
01/2015
1palbociclibIBA
01/2015
1Cyclin D1IBA
01/2015
1silvestrolIBA
09/2014

Therapy/Procedure

31Therapeutics
01/2022 - 01/2002
7Drug Therapy (Chemotherapy)
11/2018 - 01/2013
2Combined Modality Therapy
01/2017 - 10/2016
2Hematopoietic Stem Cell Transplantation
08/2015 - 01/2015
2Lasers (Laser)
03/2012 - 07/2003
2Ligation
02/2011 - 05/2010
1Investigational Therapies (Experimental Therapy)
01/2020
1Precision Medicine
01/2016
1Immunotherapy
01/2016
1Salvage Therapy
08/2015